Skip to main content

Rain Therapeutics, Inc. (RAIN)

NASDAQ: RAIN · IEX Real-Time Price · USD
13.59 -0.10 (-0.73%)
Oct 21, 2021 11:46 AM EDT - Market open
Market Cap362.33M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out20.83M
EPS (ttm)-3.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,988
Open13.52
Previous Close13.69
Day's Range13.42 - 13.97
52-Week Range11.57 - 23.90
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About RAIN

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other...

IndustryBiotechnology
IPO DateApr 23, 2021
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolRAIN
Full Company Profile

Financial Performance

Financial Statements

News

Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference ...

Presentations highlight potential of the oral MDM2 inhibitor, milademetan, in advanced cancers with MDM2 amplification, GATA3 mutant ER-positive breast cancer, and Merkel cell carcinoma Presentations hi...

2 weeks ago - GlobeNewsWire

Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellan...

4 weeks ago - GlobeNewsWire

Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

NEWARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellank...

1 month ago - GlobeNewsWire

Rain Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Progress

First patient dosed in Phase 3 registrational trial (MANTRA) evaluating milademetan (RAIN-32) in patients with dedifferentiated (“DD”) liposarcoma (“LPS”)

2 months ago - GlobeNewsWire

Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Recent Progress on August 10, 2021

NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial resul...

2 months ago - GlobeNewsWire

4 Global IPO Stocks Outperforming the S&P 500 Over the Past Month

In light of the global initial public offering market recording its strongest second quarter in two decades by volume and proceeds, four stocks that had their IPO during the past three months and outper...

Other symbols:HOWL
2 months ago - GuruFocus

Rain Therapeutics Announces Patient Referral Partnership for the Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32

Clinical trial for MDM2-amplified cancers expected to commence in second half of 2021 Clinical trial for MDM2-amplified cancers expected to commence in second half of 2021

4 months ago - GlobeNewsWire

Rain Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, ...

4 months ago - GlobeNewsWire

Rain Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Progress

Completed initial public offering ("IPO") with net proceeds of $121.9 million

4 months ago - GlobeNewsWire

Rain Therapeutics Appoints Robert Doebele, M.D., Ph.D. as President

Dr. Doebele, Rain co-founder, will continue to serve as chief scientific officer Dr. Doebele, Rain co-founder, will continue to serve as chief scientific officer

5 months ago - GlobeNewsWire

Rain Therapeutics Announces Pricing of Initial Public Offering

NEWARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the pricing of its initial public...

5 months ago - GlobeNewsWire

Rain Plans $100 Million IPO, Phase III Trial for Lead Precision Cancer Therapy

The news comes months after the company closed a $63 million Series B and inlicensed RAIN-32 from Daiichi Sankyo.

6 months ago - BioSpace

Rain Ther­a­peu­tics head­lines newest slate of IPO-bound biotechs with $100M pen­ciled in for lead on­col­o­gy pro­gram

A fresh slate of biotech IPOs has filed to go public as the calendar turns toward the second quarter.

6 months ago - EndPoints News

Rain Therapeutics IPO Registration Document (S-1)

Rain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC